Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis
Enzastaurin (LY317615.HCl) is currently in a phase III registration trial for diffuse large B-Cell lymphoma and numerous phase II clinical trials. Enzastaurin suppresses angiogenesis and induces apoptosis in multiple human tumor cell lines by inhibiting protein kinase C (PKC) and phosphoinositide 3-...
Saved in:
Published in | Molecular cancer therapeutics Vol. 9; no. 12; pp. 3158 - 3163 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.12.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Enzastaurin (LY317615.HCl) is currently in a phase III registration trial for diffuse large B-Cell lymphoma and numerous phase II clinical trials. Enzastaurin suppresses angiogenesis and induces apoptosis in multiple human tumor cell lines by inhibiting protein kinase C (PKC) and phosphoinositide 3-kinase (PI3K)/AKT pathway signaling. PI3K/AKT pathway signaling liberates eukaryotic translation initiation factor 4E (eIF4E) through the hierarchical phosphorylation of eIF4E binding proteins (4E-BP). When hypophosphorylated, 4E-BPs associate with eIF4E, preventing eIF4E from binding eIF4G, blocking the formation of the eIF4F translation initiation complex. Herein, we show that enzastaurin treatment impacts signaling throughout the AKT/mTOR pathway leading to hypophosphorylation of 4E-BP1 in cancer cells of diverse lineages (glioblastoma, colon carcinoma, and B-cell lymphoma). Accordingly, enzastaurin treatment increases the amount of eIF4E bound to 4E-BP1 and decreases association of eIF4E with eIF4G, thereby reducing eIF4F translation initiation complex levels. We therefore chose to evaluate whether this effect on 4E-BP1 was involved in enzastaurin-induced apoptosis. Remarkably, enzastaurin-induced apoptosis was blocked in cancer cells depleted of 4E-BP1 by siRNAs, or in 4EBP1/2 knockout murine embryonic fibroblasts cells. Furthermore, eIF4E expression was increased and 4E-BP1 expression was decreased in cancer cells selected for reduced sensitivity to enzastaurin-induced apoptosis. These data highlight the importance of modulating 4E-BP1 function, and eIF4F complex levels, in the direct antitumor effect of enzastaurin and suggest that 4E-BP1 function may serve as a promising determinant of enzastaurin activity. |
---|---|
AbstractList | Abstract
Enzastaurin (LY317615.HCl) is currently in a phase III registration trial for diffuse large B-Cell lymphoma and numerous phase II clinical trials. Enzastaurin suppresses angiogenesis and induces apoptosis in multiple human tumor cell lines by inhibiting protein kinase C (PKC) and phosphoinositide 3-kinase (PI3K)/AKT pathway signaling. PI3K/AKT pathway signaling liberates eukaryotic translation initiation factor 4E (eIF4E) through the hierarchical phosphorylation of eIF4E binding proteins (4E-BP). When hypophosphorylated, 4E-BPs associate with eIF4E, preventing eIF4E from binding eIF4G, blocking the formation of the eIF4F translation initiation complex. Herein, we show that enzastaurin treatment impacts signaling throughout the AKT/mTOR pathway leading to hypophosphorylation of 4E-BP1 in cancer cells of diverse lineages (glioblastoma, colon carcinoma, and B-cell lymphoma). Accordingly, enzastaurin treatment increases the amount of eIF4E bound to 4E-BP1 and decreases association of eIF4E with eIF4G, thereby reducing eIF4F translation initiation complex levels. We therefore chose to evaluate whether this effect on 4E-BP1 was involved in enzastaurin-induced apoptosis. Remarkably, enzastaurin-induced apoptosis was blocked in cancer cells depleted of 4E-BP1 by siRNAs, or in 4EBP1/2 knockout murine embryonic fibroblasts cells. Furthermore, eIF4E expression was increased and 4E-BP1 expression was decreased in cancer cells selected for reduced sensitivity to enzastaurin-induced apoptosis. These data highlight the importance of modulating 4E-BP1 function, and eIF4F complex levels, in the direct antitumor effect of enzastaurin and suggest that 4E-BP1 function may serve as a promising determinant of enzastaurin activity. Mol Cancer Ther; 9(12); 3158–63. ©2010 AACR. Enzastaurin (LY317615.HCl) is currently in a phase III registration trial for diffuse large B-Cell lymphoma and numerous phase II clinical trials. Enzastaurin suppresses angiogenesis and induces apoptosis in multiple human tumor cell lines by inhibiting protein kinase C (PKC) and phosphoinositide 3-kinase (PI3K)/AKT pathway signaling. PI3K/AKT pathway signaling liberates eukaryotic translation initiation factor 4E (eIF4E) through the hierarchical phosphorylation of eIF4E binding proteins (4E-BP). When hypophosphorylated, 4E-BPs associate with eIF4E, preventing eIF4E from binding eIF4G, blocking the formation of the eIF4F translation initiation complex. Herein, we show that enzastaurin treatment impacts signaling throughout the AKT/mTOR pathway leading to hypophosphorylation of 4E-BP1 in cancer cells of diverse lineages (glioblastoma, colon carcinoma, and B-cell lymphoma). Accordingly, enzastaurin treatment increases the amount of eIF4E bound to 4E-BP1 and decreases association of eIF4E with eIF4G, thereby reducing eIF4F translation initiation complex levels. We therefore chose to evaluate whether this effect on 4E-BP1 was involved in enzastaurin-induced apoptosis. Remarkably, enzastaurin-induced apoptosis was blocked in cancer cells depleted of 4E-BP1 by siRNAs, or in 4EBP1/2 knockout murine embryonic fibroblasts cells. Furthermore, eIF4E expression was increased and 4E-BP1 expression was decreased in cancer cells selected for reduced sensitivity to enzastaurin-induced apoptosis. These data highlight the importance of modulating 4E-BP1 function, and eIF4F complex levels, in the direct antitumor effect of enzastaurin and suggest that 4E-BP1 function may serve as a promising determinant of enzastaurin activity. Enzastaurin (LY317615.HCl) is currently in a phase III registration trial for diffuse large B-Cell lymphoma and numerous phase II clinical trials. Enzastaurin suppresses angiogenesis and induces apoptosis in multiple human tumor cell lines by inhibiting protein kinase C (PKC) and phosphoinositide 3-kinase (PI3K)/AKT pathway signaling. PI3K/AKT pathway signaling liberates eukaryotic translation initiation factor 4E (eIF4E) through the hierarchical phosphorylation of eIF4E binding proteins (4E-BP). When hypophosphorylated, 4E-BPs associate with eIF4E, preventing eIF4E from binding eIF4G, blocking the formation of the eIF4F translation initiation complex. Herein, we show that enzastaurin treatment impacts signaling throughout the AKT/mTOR pathway leading to hypophosphorylation of 4E-BP1 in cancer cells of diverse lineages (glioblastoma, colon carcinoma, and B-cell lymphoma). Accordingly, enzastaurin treatment increases the amount of eIF4E bound to 4E-BP1 and decreases association of eIF4E with eIF4G, thereby reducing eIF4F translation initiation complex levels. We therefore chose to evaluate whether this effect on 4E-BP1 was involved in enzastaurin-induced apoptosis. Remarkably, enzastaurin-induced apoptosis was blocked in cancer cells depleted of 4E-BP1 by siRNAs, or in 4EBP1/2 knockout murine embryonic fibroblasts cells. Furthermore, eIF4E expression was increased and 4E-BP1 expression was decreased in cancer cells selected for reduced sensitivity to enzastaurin-induced apoptosis. These data highlight the importance of modulating 4E-BP1 function, and eIF4F complex levels, in the direct antitumor effect of enzastaurin and suggest that 4E-BP1 function may serve as a promising determinant of enzastaurin activity. Mol Cancer Ther; 9(12); 3158-63. [copy ]2010 AACR. |
Author | Furic, Luc Konicek, Bruce W Parsons, Stephen H Sonenberg, Nahum Graff, Jeremy R Dumstorf, Chad A McNulty, Ann M |
Author_xml | – sequence: 1 givenname: Chad A surname: Dumstorf fullname: Dumstorf, Chad A email: graff_jeremy@lilly.com organization: Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285. graff_jeremy@lilly.com – sequence: 2 givenname: Bruce W surname: Konicek fullname: Konicek, Bruce W – sequence: 3 givenname: Ann M surname: McNulty fullname: McNulty, Ann M – sequence: 4 givenname: Stephen H surname: Parsons fullname: Parsons, Stephen H – sequence: 5 givenname: Luc surname: Furic fullname: Furic, Luc – sequence: 6 givenname: Nahum surname: Sonenberg fullname: Sonenberg, Nahum – sequence: 7 givenname: Jeremy R surname: Graff fullname: Graff, Jeremy R |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20971826$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkMtOwzAQRS1URB_wCaDsWBn8TJwlVOUhtYJFkdhFU8eWjBK7xM4Cvp6mLWxZzejOmRnpTNHIB28QuqTkhlKpbqnkEhc05zetTpgSTATlJ2iyyxVWkorRvj8wYzSN8YMQqkpGz9CYkbKgiuUT9L4Kdd9AcsFnwWZige9faWZ7r_cRxAwy3bnkNDRZbZLpWufBpwE2_htigr5zHjtf99rUGWzDNoXo4jk6tdBEc3GsM_T2sFjPn_Dy5fF5frfEWkiesCKlsloWXNLCQmkYFCUHpnMmBFC7G-UcNtZymUNplSJQl3XBRGEKqUESPkPXh7vbLnz2JqaqdVGbpgFvQh-rUoqc5JL9TyqqcsGJYDtSHkjdhRg7Y6tt51rovipKqsF-NZitBrPVar4e0sH-bu_q-KHftKb-2_rVzX8AfLuCNg |
CitedBy_id | crossref_primary_10_1007_s12308_013_0188_6 crossref_primary_10_1002_anie_201603254 crossref_primary_10_18632_oncotarget_5462 crossref_primary_10_1073_pnas_1310230110 crossref_primary_10_3892_or_2013_2512 crossref_primary_10_1038_onc_2013_153 crossref_primary_10_1111_j_1365_2559_2012_04236_x crossref_primary_10_3390_cells8121542 crossref_primary_10_1517_13543784_2011_590130 crossref_primary_10_1007_s13206_011_5203_3 crossref_primary_10_1371_journal_pone_0057431 crossref_primary_10_18632_oncotarget_15201 crossref_primary_10_3390_jcm8040560 crossref_primary_10_1038_s41419_017_0001_z crossref_primary_10_1111_j_1464_410X_2012_11569_x crossref_primary_10_3109_10428194_2011_634041 crossref_primary_10_1021_acs_jmedchem_3c00636 crossref_primary_10_1002_ange_201603254 crossref_primary_10_1093_bioinformatics_btw295 crossref_primary_10_3390_cancers14102397 crossref_primary_10_1007_s10555_012_9349_9 crossref_primary_10_3390_antiox11091845 crossref_primary_10_1016_j_semcancer_2017_04_011 crossref_primary_10_4161_15384101_2015_945383 crossref_primary_10_1634_theoncologist_2012_0218 |
Cites_doi | 10.1016/j.ccr.2009.09.025 10.1158/1535-7163.MCT-05-0465 10.1158/0008-5472.CAN-07-3195 10.1016/j.lungcan.2009.02.001 10.1002/jso.20037 10.1158/0008-5472.CAN-05-0071 10.1128/MCB.15.9.4990 10.1002/j.1460-2075.1995.tb00257.x 10.1158/1078-0432.CCR-06-1560 10.1158/0008-5472.CAN-09-1923 10.1016/j.ccr.2010.05.023 10.1080/10428190802078289 10.1172/JCI29528 10.1038/sj.jid.5700322 10.1158/0008-5472.CAN-08-3472 10.1172/JCI32044 10.1101/gad.912401 10.1016/j.ccr.2010.01.021 10.1038/sj.bjc.6604566 10.1002/(SICI)1097-0142(19970615)79:12<2385::AID-CNCR13>3.0.CO;2-N 10.1182/blood-2006-10-054577 10.1200/JCO.2005.05.3447 10.1158/0008-5472.CAN-05-2879 10.1016/S0278-2391(99)90676-6 10.1111/j.1471-4159.2008.05586.x 10.1038/sj.onc.1207545 10.1016/j.ccr.2004.05.024 10.1182/blood-2009-02-205153 10.1002/cncr.22195 10.1016/j.cell.2006.11.046 10.1200/JCO.2006.09.3146 10.1038/sj.onc.1207549 |
ContentType | Journal Article |
Copyright | 2010 AACR. |
Copyright_xml | – notice: 2010 AACR. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7QO 8FD FR3 P64 |
DOI | 10.1158/1535-7163.mct-10-0413 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | CrossRef MEDLINE Engineering Research Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-8514 |
EndPage | 3163 |
ExternalDocumentID | 10_1158_1535_7163_MCT_10_0413 20971826 |
Genre | Journal Article |
GroupedDBID | --- .55 123 18M 2FS 2WC 34G 39C 3O- 53G 5RE 5VS AAJMC ABOCM ACGFO ACIWK ACPRK ADBBV ADCOW AENEX AFHIN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P GX1 H13 H~9 IH2 KQ8 L7B MVM NPM OK1 P2P QTD RCR RHF RHI TR2 W8F WHG WOQ X7M YBU ZGI ZXP AAYXX CITATION 7X8 7QO 8FD FR3 P64 |
ID | FETCH-LOGICAL-c453t-8098fc573517fa9e2a793a2c6244a1ffc563abff356a9f880ad9d7247e75ca503 |
ISSN | 1535-7163 1538-8514 |
IngestDate | Tue Aug 27 04:56:35 EDT 2024 Fri Aug 16 11:28:56 EDT 2024 Fri Aug 23 03:44:34 EDT 2024 Sat Sep 28 07:56:29 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Language | English |
License | 2010 AACR. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c453t-8098fc573517fa9e2a793a2c6244a1ffc563abff356a9f880ad9d7247e75ca503 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
OpenAccessLink | http://escholarship.mcgill.ca/downloads/2n49t712d |
PMID | 20971826 |
PQID | 818643042 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_954606520 proquest_miscellaneous_818643042 crossref_primary_10_1158_1535_7163_MCT_10_0413 pubmed_primary_20971826 |
PublicationCentury | 2000 |
PublicationDate | 2010-12-01 |
PublicationDateYYYYMMDD | 2010-12-01 |
PublicationDate_xml | – month: 12 year: 2010 text: 2010-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular cancer therapeutics |
PublicationTitleAlternate | Mol Cancer Ther |
PublicationYear | 2010 |
References | Rieger (2022060801352508700_bib28) 2008; 106 Castellvi (2022060801352508700_bib20) 2006; 107 Graff (2022060801352508700_bib21) 2007; 117 Sorrells (2022060801352508700_bib13) 1999; 57 Assouline (2022060801352508700_bib22) 2009; 114 Jacobson (2022060801352508700_bib18) 2006; 66 Rizvi (2022060801352508700_bib31) 2006; 5 Tekle (2022060801352508700_bib2) 2008; 99 Le (2022060801352508700_bib25) 2007; 117 Avdulov (2022060801352508700_bib16) 2004; 5 Mamane (2022060801352508700_bib6) 2004; 23 Hsieh (2022060801352508700_bib8) 2010; 17 Graff (2022060801352508700_bib1) 2005; 65 Carducci (2022060801352508700_bib27) 2006; 24 Rojo (2022060801352508700_bib19) 2007; 13 Gingras (2022060801352508700_bib5) 2001; 15 Wang (2022060801352508700_bib10) 2009; 66 Rousseau (2022060801352508700_bib17) 1996; 13 Neri (2022060801352508700_bib32) 2008; 49 De Benedetti (2022060801352508700_bib7) 2004; 23 Moreau (2022060801352508700_bib33) 2007; 109 Mader (2022060801352508700_bib4) 1999; 15 Haghighat (2022060801352508700_bib3) 1995; 14 Kim (2022060801352508700_bib15) 2009; 69 Moerke (2022060801352508700_bib23) 2007; 128 Robertson (2022060801352508700_bib26) 2007; 25 Lee (2022060801352508700_bib30) 2008; 68 She (2022060801352508700_bib24) 2010; 18 Chen (2022060801352508700_bib11) 2004; 86 Li (2022060801352508700_bib12) 1997; 79 Petroulakis (2022060801352508700_bib14) 2009; 16 Graff (2022060801352508700_bib9) 2009; 69 Querfeld (2022060801352508700_bib29) 2006; 126 |
References_xml | – volume: 16 start-page: 439 year: 2009 ident: 2022060801352508700_bib14 article-title: p53-dependent translational control of senescence and transformation via 4E-BPs publication-title: Cancer Cell doi: 10.1016/j.ccr.2009.09.025 contributor: fullname: Petroulakis – volume: 13 start-page: 2415 year: 1996 ident: 2022060801352508700_bib17 article-title: The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth publication-title: Oncogene contributor: fullname: Rousseau – volume: 5 start-page: 1783 year: 2006 ident: 2022060801352508700_bib31 article-title: Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-05-0465 contributor: fullname: Rizvi – volume: 68 start-page: 1916 year: 2008 ident: 2022060801352508700_bib30 article-title: Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-3195 contributor: fullname: Lee – volume: 66 start-page: 237 year: 2009 ident: 2022060801352508700_bib10 article-title: Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma publication-title: Lung Cancer doi: 10.1016/j.lungcan.2009.02.001 contributor: fullname: Wang – volume: 86 start-page: 22 year: 2004 ident: 2022060801352508700_bib11 article-title: Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome publication-title: J Surg Oncol doi: 10.1002/jso.20037 contributor: fullname: Chen – volume: 65 start-page: 7462 year: 2005 ident: 2022060801352508700_bib1 article-title: The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-0071 contributor: fullname: Graff – volume: 15 start-page: 4990 year: 1999 ident: 2022060801352508700_bib4 article-title: The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins publication-title: Mol Cell Biol doi: 10.1128/MCB.15.9.4990 contributor: fullname: Mader – volume: 14 start-page: 5701 year: 1995 ident: 2022060801352508700_bib3 article-title: Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E publication-title: EMBO J doi: 10.1002/j.1460-2075.1995.tb00257.x contributor: fullname: Haghighat – volume: 13 start-page: 81 year: 2007 ident: 2022060801352508700_bib19 article-title: 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-1560 contributor: fullname: Rojo – volume: 69 start-page: 8455 year: 2009 ident: 2022060801352508700_bib15 article-title: Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-1923 contributor: fullname: Kim – volume: 18 start-page: 39 year: 2010 ident: 2022060801352508700_bib24 article-title: 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.05.023 contributor: fullname: She – volume: 49 start-page: 1374 year: 2008 ident: 2022060801352508700_bib32 article-title: The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines publication-title: Leuk Lymphoma doi: 10.1080/10428190802078289 contributor: fullname: Neri – volume: 117 start-page: 387 year: 2007 ident: 2022060801352508700_bib25 article-title: Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2 publication-title: J Clin Invest doi: 10.1172/JCI29528 contributor: fullname: Le – volume: 126 start-page: 1641 year: 2006 ident: 2022060801352508700_bib29 article-title: The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway publication-title: J Invest Dermatol doi: 10.1038/sj.jid.5700322 contributor: fullname: Querfeld – volume: 69 start-page: 3866 year: 2009 ident: 2022060801352508700_bib9 article-title: eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-3472 contributor: fullname: Graff – volume: 117 start-page: 2638 year: 2007 ident: 2022060801352508700_bib21 article-title: Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity publication-title: J Clin Invest doi: 10.1172/JCI32044 contributor: fullname: Graff – volume: 15 start-page: 2852 year: 2001 ident: 2022060801352508700_bib5 article-title: Hierarchical phosphorylation of the translation inhibitor 4E-BP1 publication-title: Genes Dev doi: 10.1101/gad.912401 contributor: fullname: Gingras – volume: 17 start-page: 249 year: 2010 ident: 2022060801352508700_bib8 article-title: Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E publication-title: Cancer Cells doi: 10.1016/j.ccr.2010.01.021 contributor: fullname: Hsieh – volume: 99 start-page: 750 year: 2008 ident: 2022060801352508700_bib2 article-title: Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604566 contributor: fullname: Tekle – volume: 79 start-page: 2385 year: 1997 ident: 2022060801352508700_bib12 article-title: Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19970615)79:12<2385::AID-CNCR13>3.0.CO;2-N contributor: fullname: Li – volume: 109 start-page: 4964 year: 2007 ident: 2022060801352508700_bib33 article-title: Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia publication-title: Blood doi: 10.1182/blood-2006-10-054577 contributor: fullname: Moreau – volume: 24 start-page: 4092 year: 2006 ident: 2022060801352508700_bib27 article-title: Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.3447 contributor: fullname: Carducci – volume: 66 start-page: 4256 year: 2006 ident: 2022060801352508700_bib18 article-title: Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-2879 contributor: fullname: Jacobson – volume: 57 start-page: 294 year: 1999 ident: 2022060801352508700_bib13 article-title: Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers publication-title: J Oral Maxillofac Surg doi: 10.1016/S0278-2391(99)90676-6 contributor: fullname: Sorrells – volume: 106 start-page: 2436 year: 2008 ident: 2022060801352508700_bib28 article-title: Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL publication-title: J Neurochem doi: 10.1111/j.1471-4159.2008.05586.x contributor: fullname: Rieger – volume: 23 start-page: 3189 year: 2004 ident: 2022060801352508700_bib7 article-title: eIF-4E expression and its role in malignancies and metastases publication-title: Oncogene doi: 10.1038/sj.onc.1207545 contributor: fullname: De Benedetti – volume: 5 start-page: 553 year: 2004 ident: 2022060801352508700_bib16 article-title: Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells publication-title: Cancer Cell doi: 10.1016/j.ccr.2004.05.024 contributor: fullname: Avdulov – volume: 114 start-page: 257 year: 2009 ident: 2022060801352508700_bib22 article-title: Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin publication-title: Blood doi: 10.1182/blood-2009-02-205153 contributor: fullname: Assouline – volume: 107 start-page: 1801 year: 2006 ident: 2022060801352508700_bib20 article-title: Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer publication-title: Cancer doi: 10.1002/cncr.22195 contributor: fullname: Castellvi – volume: 128 start-page: 257 year: 2007 ident: 2022060801352508700_bib23 article-title: Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G publication-title: Cell doi: 10.1016/j.cell.2006.11.046 contributor: fullname: Moerke – volume: 25 start-page: 1741 year: 2007 ident: 2022060801352508700_bib26 article-title: Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.3146 contributor: fullname: Robertson – volume: 23 start-page: 3172 issue: 18 year: 2004 ident: 2022060801352508700_bib6 article-title: eIF4E–from translation to transformation publication-title: Oncogene doi: 10.1038/sj.onc.1207549 contributor: fullname: Mamane |
SSID | ssj0018921 |
Score | 2.166721 |
Snippet | Enzastaurin (LY317615.HCl) is currently in a phase III registration trial for diffuse large B-Cell lymphoma and numerous phase II clinical trials. Enzastaurin... Abstract Enzastaurin (LY317615.HCl) is currently in a phase III registration trial for diffuse large B-Cell lymphoma and numerous phase II clinical trials.... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 3158 |
SubjectTerms | Animals Apoptosis - drug effects Carrier Proteins - metabolism Cell Line, Tumor Drug Screening Assays, Antitumor Eukaryotic Initiation Factor-4F - metabolism Gene Knockout Techniques Humans Indoles - pharmacology Mice Mice, Knockout Phosphoproteins - metabolism Phosphorylation - drug effects Proto-Oncogene Proteins c-akt - metabolism Signal Transduction - drug effects TOR Serine-Threonine Kinases - metabolism |
Title | Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/20971826 https://search.proquest.com/docview/818643042 https://search.proquest.com/docview/954606520 |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF7cFEovoenTbVP20FuQa-1L0jENDiGJ3BRk8E2spV0oaSVTSZf8-szobeqQthdhVssaZj5G38zOg5DPTHMvUZvUsaBvR3hWOb6fMkcwo5SdG_CJMDQQLtXFSlyu5XoysaOsparczJK7vXUl_6NVWAO9YpXsP2i2PxQW4DfoF56gYXj-lY7DPG2nbyHnEwvn6417gl-qZvx3gZWP3SiDdMh7wc0mu9NADDHW7oBbXmEagN7m2zIvfhRjxhp283MxPywxdU5iV7E1DKWvfmGWpW0v8NMhQnqFrXfNbQ-jkz6mEybL6mczkuA0y4ao7I1GH6AYpaC1BRRtbGInz8MM9hRInRgb3GCMKzayntxt2ri3X2LuNrbvTysvsXIBzpYOuHt8Fp5FdX6daMpad7tqL7_F56vr6zharKMn5CnzAompn1ffh9smP2BuW90FR3_Ze_Aub3nAGalJSfSCHLbeBD1toHFEJiZ7SZ6Fbb7EK7IeEEJzSxuE0A4hVBdU0w4hdIQQ3LwHIbRHyGuyOl9EZxdOO0vDSYTkJRCRwLeJ9Lh0PasDwzQYZs0SBfROuxZeKa431nKpdGDBqOs0SD0mPONJnJrB35CDLM_MO0KB4HHruSZl2gprReBy4MDAhJRN5qlyp2TWSSreNi1T4trVlH6Moo1RtDGIFldRtFNCO3nGYNzwxkpnJq-KGNstCgy4PbwlkAJ8cMnmU_K2UUX_pwz7o4H7_P7x8z-Q5wN-P5KD8ndljoFtlptPNVTuAQbHf4Y |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Modulation+of+4E-BP1+function+as+a+critical+determinant+of+enzastaurin-induced+apoptosis&rft.jtitle=Molecular+cancer+therapeutics&rft.au=Dumstorf%2C+Chad+A&rft.au=Konicek%2C+Bruce+W&rft.au=McNulty%2C+Ann+M&rft.au=Parsons%2C+Stephen+H&rft.date=2010-12-01&rft.eissn=1538-8514&rft.volume=9&rft.issue=12&rft.spage=3158&rft.epage=3163&rft_id=info:doi/10.1158%2F1535-7163.MCT-10-0413&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-7163&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-7163&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-7163&client=summon |